Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Businessweek Archives

Oh What A Headache At Syntex


In Business This Week

OH WHAT A HEADACHE AT SYNTEX

It's a good thing Syntex makes painkillers. On June 2, company execs got the bad news: An advisory committee to the Food & Drug Administration recommended that Syntex' flagship product, the popular arthritis drug Naprosyn, not be approved for over-the-counter use. Syntex stands to lose big in December, when Naprosyn, a billion-dollar drug, goes off patent. The company had teamed up with Procter & Gamble hoping to sell Naprosyn without a prescription, but the FDA committee had concerns over the lack of data demonstrating that the drug is safe in OTC doses. Given Syntex' nearly empty new-product pipeline, this setback sets it way back.EDITED BY JULIE TILSNER


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus